老年亚临床甲状腺功能亢进症的治疗:放射性碘与长期甲巯咪唑治疗的比较
本研究为随机平行组试验,纳入83例65岁及以上、促甲状腺激素<0.1 mU/L的亚临床甲状腺功能亢进症患者,分别接受放射性碘或长期甲巯咪唑治疗。放射性碘组60个月后66%甲减、34%甲状腺功能正常;甲巯咪唑组94%甲状腺功能正常。两种治疗均有效且安全。
要点
- 放射性碘固定剂量15 mCi后60个月,66%患者甲减,34%维持甲状腺功能正常。
- 长期低剂量甲巯咪唑滴定治疗60个月后,94%患者甲状腺功能正常。
- 两组治疗前4个月均有轻微不良事件,60个月随访期间无死亡或严重副作用。
核心结论
- 放射性碘和长期低剂量甲巯咪唑治疗对老年亚临床甲状腺功能亢进症均有效且安全。
研究设计与样本
- 随机平行组试验,从306例65岁及以上亚临床甲状腺功能亢进症患者中纳入83例促甲状腺激素<0.1 mU/L者,随机分为放射性碘组41例和长期甲巯咪唑组42例。
主要发现
- 放射性碘组和甲巯咪唑组分别有3例和4例因副作用、选择其他治疗方式及未返回随访而被排除,分别有35例和36例完成60个月随访。
- 放射性碘组在固定剂量15 mCi后60个月,23例(66%)发生甲减,12例(34%)维持甲状腺功能正常。
- 甲巯咪唑组起始剂量为每日10 mg,采用滴定法,连续治疗1、2、3、4、5年后剂量分别降至4.9±1.0、4.3±1.0、4.4±1.4、4.3±1.8和3.7±1.3 mg。
- 研究结束时,甲巯咪唑组34例(94%)甲状腺功能正常,2例弥漫性甲状腺肿患者在接受甲巯咪唑治疗期间发生自发性甲减。
- 两组在治疗前4个月均出现轻微不良事件,60个月随访期间未观察到死亡或严重副作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: This study aimed to compare the effectiveness and safety of radioiodine (RAI) and long-term methimazole (MMI) in the treatment of subclinical hyperthyroidism (SH) in the elderly. Methods: From 306 patients, aged ≥65 years, with SH, 83 patients with thyrotropin <0.1 mU/L entered the study. In this randomized parallel-group trial, 41 and 42 patients were randomized to either RAI or long-term MMI treatment, respectively. Results: In the RAI and MMI groups, 3 and 4 patients were excluded due to side effects, choosing other modes of treatment, and not returning for follow-up; 35 and 36 patients completed 60 months of follow-up, respectively. In the RAI group, 23 (66%) became hypothyroid, and 12 (34%) remained euthyroid 60 months after a fixed dose of 15 mCi RAI. In the MMI group, the starting dose was 10 mg daily and decreased to 4.9 ± 1.0, 4.3 ± 1.0, 4.4 ± 1.4, 4.3 ± 1.8, and 3.7 ± 1.3 mg after 1, 2, 3, 4, and 5 years of continuous MMI treatment, employing titration method. By the end of study, 34 (94%) patients were euthyroid and 2 patients with diffuse goiter developed spontaneous hypothyroidism with MMI treatment. Minor adverse events occurred in both groups in the first four months of treatment. No death or serious side effects were observed during 60 months of follow-up. Conclusions: Both RAI and long-term low-dose MMI therapies are effective and safe for treatment of SH in the elderly.
引用
- Azizi F, Abdi H, Cheraghi L, et al. Treatment of Subclinical Hyperthyroidism in the Elderly: Comparison of Radioiodine and Long-Term Methimazole Treatment. Thyroid. 2020. PMID: 32811342. doi:10.1089/thy.2020.0433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。